Skip to main content
HRES 709 113th Congress House Health Advanced technology and technological innovations Biological and life sciences Department of Health and Human Services Drug safety, medical device, and laboratory regulation Executive agency funding and structure Food and Drug Administration (FDA) Health programs administration and funding Health technology, devices, supplies Medical research Research administration and funding Research and development

Recognizing the importance of transformative breakthroughs in biomedicine, biotechnology, and life sciences in the diagnosis, management, curing, and treatment of illness and the existence of a ''Valley of Death'' in biotechnology and life sciences funding that stifles innovation and impedes translational medical research.

Introduced: July 31, 2014 Introduced by: Vargas, Juan Democratic · California See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 1, 2014
Referred to the Subcommittee on Health.
Jul 31, 2014
Referred to the House Committee on Energy and Commerce.
Jul 31, 2014
Introduced in House
 Plain-English summary Congressional Research Service

Recognizes the value of biomedicine, biotechnology, and life sciences; the challenges those industries face; and ways those challenges can be addressed.

What's happening now August 1, 2014

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 2
All 2 Democratic 2